The first MTA was signed by Rosetta Genomics a diagnostic company in Israel specialized in diagnostic, prognostic, and predictive testing and the department of pathology at Erasmus Medical Centre, the Netherlands led by Prof Zwarthoff. The collaboration includes FFPE samples from transuretheral resection. This MTA signs the second collaboration between Rosetta Genomics and an EATRIS institution.
The second MTA signed concerned plasma samples and associated data for the development of non-invasive predictive diagnostic tool in locally advanced rectal cancer developed by Prestizia, the miRNA platform of Theradiag (France). The agreement was signed with the biobank platform of IdiPAZ, Spain.